IMAC (IMAC) Competitors $0.04 -0.01 (-12.85%) As of 06/12/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock IMAC vs. ACON, CANF, KZIA, EVAX, LIXT, SNPX, SONN, NUWE, APTO, and GCTKShould you be buying IMAC stock or one of its competitors? The main competitors of IMAC include Aclarion (ACON), Can-Fite BioPharma (CANF), Kazia Therapeutics (KZIA), Evaxion Biotech A/S (EVAX), Lixte Biotechnology (LIXT), Synaptogenix (SNPX), Sonnet BioTherapeutics (SONN), Nuwellis (NUWE), Aptose Biosciences (APTO), and GlucoTrack (GCTK). These companies are all part of the "medical" sector. IMAC vs. Its Competitors Aclarion Can-Fite BioPharma Kazia Therapeutics Evaxion Biotech A/S Lixte Biotechnology Synaptogenix Sonnet BioTherapeutics Nuwellis Aptose Biosciences GlucoTrack IMAC (NASDAQ:IMAC) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, community ranking, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends. Does the media favor IMAC or ACON? In the previous week, IMAC and IMAC both had 2 articles in the media. Aclarion's average media sentiment score of 1.43 beat IMAC's score of 0.00 indicating that Aclarion is being referred to more favorably in the news media. Company Overall Sentiment IMAC Neutral Aclarion Positive Do analysts rate IMAC or ACON? Aclarion has a consensus target price of $11,758.50, indicating a potential upside of 157,944.35%. Given Aclarion's stronger consensus rating and higher possible upside, analysts clearly believe Aclarion is more favorable than IMAC.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IMAC 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Aclarion 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher earnings and valuation, IMAC or ACON? Aclarion has lower revenue, but higher earnings than IMAC. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIMAC$15.22M0.07-$10.54MN/AN/AAclarion$54.60K79.30-$4.91MN/AN/A Does the MarketBeat Community favor IMAC or ACON? IMAC received 67 more outperform votes than Aclarion when rated by MarketBeat users. Likewise, 60.17% of users gave IMAC an outperform vote while only 57.14% of users gave Aclarion an outperform vote. CompanyUnderperformOutperformIMACOutperform Votes7160.17% Underperform Votes4739.83% AclarionOutperform Votes457.14% Underperform Votes342.86% Which has more risk & volatility, IMAC or ACON? IMAC has a beta of -0.88, suggesting that its share price is 188% less volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Do insiders and institutionals have more ownership in IMAC or ACON? 24.3% of IMAC shares are held by institutional investors. Comparatively, 7.5% of Aclarion shares are held by institutional investors. 10.0% of IMAC shares are held by insiders. Comparatively, 0.8% of Aclarion shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is IMAC or ACON more profitable? IMAC has a net margin of -75.40% compared to Aclarion's net margin of -12,845.05%. IMAC's return on equity of -52.17% beat Aclarion's return on equity.Company Net Margins Return on Equity Return on Assets IMAC-75.40% -52.17% -34.51% Aclarion -12,845.05%-422.87%-201.15% SummaryIMAC beats Aclarion on 8 of the 14 factors compared between the two stocks. Get IMAC News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMAC vs. The Competition Export to ExcelMetricIMACSpecialty Outpatient Clinics IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.06M$932.00K$5.58B$8.50BDividend YieldN/AN/A5.28%4.17%P/E RatioN/AN/A27.1919.64Price / Sales0.070.07408.78152.17Price / CashN/AN/A38.3234.64Price / Book0.060.066.974.60Net Income-$10.54M-$10.54M$3.23B$248.06M7 Day PerformanceN/AN/A-0.88%-1.02%1 Month PerformanceN/AN/A7.81%3.51%1 Year PerformanceN/AN/A31.53%12.68% IMAC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMACIMACN/A$0.04-12.9%N/A-98.5%$1.06M$15.22M0.00106Gap DownACONAclarion2.4816 of 5 stars$6.66+2.8%$11,758.50+176,454.1%-99.7%$3.88M$54.60K0.007Short Interest ↓Gap DownCANFCan-Fite BioPharma3.1723 of 5 stars$1.10+1.9%$14.00+1,178.5%-65.6%$3.88M$674K-0.618Short Interest ↓Gap UpKZIAKazia Therapeutics3.6106 of 5 stars$3.78-0.5%$57.50+1,421.2%-21.6%$3.83M$2.31M0.0012News CoveragePositive NewsAnalyst ForecastShort Interest ↓EVAXEvaxion Biotech A/S1.9875 of 5 stars$2.72+10.6%$10.00+267.6%-82.5%$3.82M$3.29M-1.8860Short Interest ↑Gap UpLIXTLixte Biotechnology1.0321 of 5 stars$1.41+20.5%N/A-49.2%$3.78MN/A-0.824Short Interest ↓SNPXSynaptogenix2.1653 of 5 stars$2.67+6.0%$14.00+424.3%+13.0%$3.71MN/A-0.264Short Interest ↑High Trading VolumeSONNSonnet BioTherapeutics2.8225 of 5 stars$1.17flat$20.00+1,609.4%-34.1%$3.70M$1M0.0010News CoverageShort Interest ↓NUWENuwellis3.0956 of 5 stars$0.85-1.7%$17.00+1,911.8%-95.8%$3.70M$8.79M-0.0170Gap DownAPTOAptose BiosciencesN/AN/A$6.00+∞N/A$3.66MN/A-0.5831Gap DownHigh Trading VolumeGCTKGlucoTrack1.3414 of 5 stars$0.13-1.9%N/A-99.8%$3.65MN/A0.005Short Interest ↓Gap Down Related Companies and Tools Related Companies Aclarion Competitors Can-Fite BioPharma Competitors Kazia Therapeutics Competitors Evaxion Biotech A/S Competitors Lixte Biotechnology Competitors Synaptogenix Competitors Sonnet BioTherapeutics Competitors Nuwellis Competitors Aptose Biosciences Competitors GlucoTrack Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMAC) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMAC Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IMAC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.